Investor Presentaiton
Oncology
Hematology
Cell Therapy
Immunology
Cardiovascular
Camzyos (myosin inhibitor)
Indication
Phase/Study
# of Patients
Heart Failure with Preserved Ejection Fraction (HFPEF)
Phase II EMBARK
-
N = 35
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Phase III ODYSSEY-HCM
-
N = 420
Camzyos
Design
Primary:
TEAES and SAES
Effect on NT-proBNP levels
Endpoints
Effect on cTnT levels (at rest)
• Camzyos
• Placebo
Primary:
• Change from baseline in Clinical Summary Score (KCCQ-23 CSS)
at Week 48
• Change from baseline in peak oxygen consumption (PVO2) at
Week 48
Secondary: Change from baseline in VE/VCO2 slope to Week 48
Status
Projected data readout 2024
CT Identifier
ll Bristol Myers Squibb Q3 2023 Results
NCT04766892
• Recruiting
.
Projected data readout 2025
NCT05582395
Not for Product Promotional Use
55View entire presentation